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Background. Human genetic variation—mostly in the human leukocyte antigen (HLA) and C–C chemokine receptor type 5 
(CCR5) regions—explains 25% of the variability in progression of human immunodeficiency virus (HIV) infection. However, it is 
also known that viral infections can modify cellular DNA methylation patterns. Therefore, changes in the methylation of cytosine-
guanine (CpG) islands might modulate progression of HIV infection.
Methods. In total, 85 samples were analyzed: 21 elite controllers (EC), 21 subjects with HIV before combination antiretroviral therapy 
(cART) (viremic, 93 325 human immunodeficiency virus type 1 [HIV-1] RNA copies/mL) and under suppressive cART (cART, median of 
17 months, <50 HIV-1 RNA copies/mL), and 22 HIV-negative donors (HIVneg). We analyzed the methylation pattern of 485 577 CpG in 
DNA from peripheral CD4+ T lymphocytes. We selected the most differentially methylated gene (TNF) and analyzed its specific methyla-
tion, messenger RNA (mRNA) expression, and plasma protein levels in 5 individuals before and after initiation of cART.
Results. We observed 129 methylated CpG sites (associated with 43 gene promoters) for which statistically significant differ-
ences were recorded in viremic versus HIVneg, 162 CpG sites (55 gene promoters) in viremic versus cART, 441 CpG sites (163 gene 
promoters) in viremic versus EC, but none in EC versus HIVneg. The TNF promoter region was hypermethylated in viremic versus 
HIVneg, cART, and EC. Moreover, we observed greater plasma levels of TNF in viremic individuals than in EC, cART, and HIVneg.
Conclusions. Our study shows that genome methylation patterns vary depending on HIV infection status and progression pro-
file and that these variations might have an impact on controlling HIV infection in the absence of cART.
Keywords.  genome-wide methylation; HIV-1 infection; HIV-1 disease progression; TNF.
Human genetic variation—mostly in the human leukocyte 
antigen (HLA) and chemokine receptor 5 (CCR5) regions—
explains 25% of the variability in progression of human immu-
nodeficiency virus (HIV) infection [1]. Epigenetic chromatin 
modification regulates cellular gene transcription and expres-
sion without changing the DNA sequence [2]. Because viral 
infections can modify cellular DNA methylation patterns [3], 
changes in the methylation of cytosine-guanine (CpG) islands 
could modulate progression of HIV infection through varia-
tions in transcription and expression of relevant genes. During 
HIV infection, the viral genome integrates into the host cellular 
genome, altering the chromatin structure and therefore poten-
tially modifying host gene expression. This virus-host interac-
tion produces changes in the epigenetic environment that affect 
both the virus and the host cell [3, 4]. Regarding DNA meth-
ylation, on the one hand, hypermethylation of the HIV 5′ long 
terminal repeat (LTR) may inhibit initiation of viral transcrip-
tion and thus favor HIV latency [5–8]. Furthermore, recent data 
suggest that methylation of 5′ LTR of HIV is associated with 
control of viral replication in a subset of individuals with HIV 
characterized as long-term nonprogressors and/or elite control-
lers (EC) [9]. On the other hand, cellular DNA methylation may 
regulate T-lymphocyte gene expression in order to favor the es-
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facilitating viral persistence [8]. Specifically, HIV can induce de 
novo methylation of host cell genes through the induction of 
DNA methyltransferase 1 (DNMT1) in vitro and in vivo [4, 10]. 
In addition, several studies showed differences in genome-wide 
DNA methylation between individuals with HIV and individ-
uals who do not have HIV [11–13]. However, there are no data 
comparing genome-wide methylation patterns in CD4+ T cells 
from HIV-negative individuals with longitudinal samples from 
individuals with HIV with different phenotypes of spontaneous 
viral control and under suppressive combination antiretroviral 
therapy (cART).
In this context, the present study aimed to evaluate the in 
vivo genome-wide DNA methylation profile in individuals 
with HIV with different phenotypes of spontaneous viral con-
trol and under suppressive cART. This approach enabled us to 
determine (i) which changes are preferentially associated with 
viremia and/or CD4 depletion (only observed in viremic indi-
viduals), (ii) which changes are reversible or nonreversible after 
viral suppression with cART (comparison between viremic and 
cART samples), and (iii) which changes might be associated 
with viral control in the absence of cART (comparison between 
ECs and viremic/cART-treated individuals).
MATERIAL AND METHODS
Study Design
In total, 42 individuals living with HIV with controlled infec-
tion (EC group, n = 21, defined as undetectable plasma viral 
load [pVL] in the absence of cART) or uncontrolled infection 
(viremic group, n = 21, defined as detectable pVL > 4 log10 cop/
mL before initiation of cART). Paired with the viremic group, 
longitudinal samples were also taken after at least 6  months 
under effective suppression with cART (cART group). Samples 
from 22 HIV-negative donors (HIVneg group) were used based 
on the cis-gender and age of the groups with HIV. The clin-
ical characteristics of the discovery cohort at sampling are 
detailed in Table 1. The specific methylation analysis was based 
on a validation cohort of 5 participants with HIV with avail-
able samples before cART and at 2 time points after initiation 
of suppressive cART (1 and 2 years after initiation). The clin-
ical characteristics of the validation cohort at sampling are de-
tailed in Supplementary Table 1. For this retrospective study, 
cryopreserved peripheral blood mononuclear cell (PBMC) 
samples from HIV-infected and HIV-negative individuals for 
the discovery and the validation cohorts were selected from the 
IrsiCaixa collection. All samples met legal requirements, in-
cluding written informed consent from participants and donors 
for the use of biological samples, and complied with the stipula-
tions of the Institutional Review Board (PI-13–024).
Procedures
CD4+ T cells purified from 85 cryopreserved PBMC samples 
were analyzed for genome-wide methylation quantification on 
an Infinium HumanMethylation450 BeadChip following the 
Illumina Infinium HD Methylation Assay Protocol. Bisulfite 
genomic sequencing of multiple clones, methylation-specific 
polymerase chain reaction (PCR), messenger RNA (mRNA) ex-
pression, and plasma levels of the selected tumor necrosis factor 
(TNF) gene were performed in samples of the validation cohort. 
The candidate CpGs contained in the methylation array were 
included in the PCR amplicon (Supplementary Table 2). The 
primer sequences are listed in Supplementary Table 3. More de-
tailed procedures are described in Supplementary Materials.
Statistical Analyses
Methylation raw data normalization was performed using 
minfi, lumi, and associated R packages following Quantile 
normalization. In the differential methylation analysis be-
tween cohorts of each CpG, a t test was used to compare 
β-value means between subject groups through pairwise 
comparisons, correcting by multiple testing (false discovery 
rate). The CpGs selected were those with adjusted values of 
Table 1. Characteristics of the Discovery Cohort at the Sampling Time Point, by Group
HIV Positive
HIV Negative (n = 22) Viremic (n = 21) cART (n = 21) EC (n = 21)
Age (years)a 32 (28–35) 34 (29–37) 44 (40–50) 31 (29–42)
Sex (n, %)     
 Men 21 (100) 21 (100) 8 (38) 4 (18)
 Women 0 0 12 (57) 9 (41)
 Missing 0 0 1 (5) 9 (41)
CD4+ T-cell counts (cells/μL)a 444 (350–565) 734 (578–808) 645 (505–1001) ND
CD4/CD8 ratioa 0·5 (0·3–0·6) 1 (0·7–1·1) ND ND
Plasma viremia (HIV RNA copies/mL) 9·4 × 104 (0·4–1·4 × 105) UD UD NA
Time since diagnosis (years)a 1 (0·8–1·3) 2·8 (2·0–3·1) 17 (8–20) NA
Time since initiation of cART (years)a 0 1·4 (1·2–1·5) 0 NA
Abbreviations: cART, combination antiretroviral therapy; EC, elite controller; HIV, human immunodeficiency virus; NA, not applicable; ND, no data; UD, undetectable (either with 25, 40, or 
50 HIV-1 RNA copies/mL threshold).
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P < .05 and an absolute methylation differential value of >0.05 
(>5%). Hypergeometric test was used to determine differen-
tially methylated gene promoter regions by comparing the 
number of differentially methylated CpGs and the number 
of CpGs tested in each region. KEGG pathway enrichment 
analysis was performed taking into account only genes with a 
differentially methylated promoter region. Wilcoxon signed 
rank test (paired comparisons: viremic vs cART) or Mann-
Whitney test (nonpaired comparisons: viremic vs EC and 
HIVneg, and EC vs HIVneg) were used to analyzed tumor 
necrosis factor (TNF) specific methylation, mRNA expres-
sion, and plasma levels using GraphPad Prism (v5.0).
RESULTS
Genome-wide Differences in Methylation Between Viremic, cART-
Suppressed, and EC Individuals With HIV and HIVneg Individuals
In order to determine whether HIV infection affects host cel-
lular genome-wide methylation, and the steadiness of such 
potential modifications, we compared the methylation level 
of 485 577 CpG sites in CD4+ T cells from viremic and paired 
cART-suppressed, EC, and HIV-negative individuals. Regarding 
methylated CpG sites for which statistically significant differ-
ences were recorded, we observed 129 differentially methylated 
CpGs between viremic and HIVneg individuals (median [min, 
max] methylation difference: 7.3 [−15.6, 16.6]%), 162 between 
viremic and cART-suppressed individuals (6.5 [5.0, 12.8]%), 
and 441 between viremic and EC individuals (6.3 [−16.4, 
13.8]%). However, we did not observe statistically significant 
differences in methylated CpG sites between EC and HIVneg 
individuals (Figure 1A–D).
To characterize the genes associated with these differen-
tially methylated CpG sites, we analyzed the CpG located in 
gene regulatory regions (5′ UTR, TSS, and the first exon were 
included) and with a methylation difference >5% (Figure 2A). 
Specifically, we detected statistically significant differences in 
methylation between viremic and HIVneg individuals in 43 
genes (Supplementary Table 4), between viremic and cART-
suppressed individuals in 55 genes (Supplementary Table 
5), and between viremic and EC individuals in 163 genes 
(Supplementary Table 6).
Within the top 15 genes per comparison, we observed 
that TNF was the most differentially methylated gene 
when comparing viremic versus HIVneg and viremic 
versus EC (padj < 1 × 10
−25), with hypermethylation ob-
served in the viremic individuals (Figure  2B). We also 
observed hypermethylation in TNF promoter when com-
paring longitudinal samples from individuals with HIV be-
fore and after viral suppression with cART (padj < 0·001), 
thus indicating that viremia-driven TNF hypermethylation 
was reverted. However, when we compared viremic versus 
cART (padj = 1·68 × 10
−8), the greatest difference in meth-
ylation was in BCL9 transcription coactivator (BCL9) with 
hypomethylation being observed only under suppressive 
cART, thus suggesting that BCL9 methylation might be af-
fected by administration of cART. Furthermore, we ob-
served hypomethylation of tripartite motif containing 
69 (TRIM69) and integrin subunit beta 2 (ITGB2) (all 
padj < 1 × 10
−7) in EC when compared with viremic individ-
uals, suggesting that the expression of these genes might be 
upregulated (hypomethylated) in EC and, therefore, have 
an impact on control of HIV infection. We also observed 
hypermethylation of lymphotoxin beta (LTB) (padj < 1 × 10
−7) 
and hypomethylation of transducing-like enhancer family 
member 1 (TLE1) (padj = 1·19 × 10
−7) when we compared vi-
remic vs HIVneg and EC, thus indicating a viremia-driven 
methylation pattern that was not reverted under suppressive 
cART. Moreover, we observed that cluster of differentiation 
2 (CD2) was hypomethylated both in EC (padj = 3·25 × 10
−4) 
and in cART (padj = 2·98 × 10
−5) compared with viremic in-
dividuals, suggesting upregulation of CD2 in virally sup-
pressed CD4+ T cells and therefore an association between 
CD2 expression with HIV latent infection.
Regarding the association between these 7 genes of interest 
and HIV, we analyzed the STRING protein interaction and 
previous bibliography related to HIV (Figure 2C). Interaction 
with HIV was previously reported for TNF, LTB, ITGB2, CD2, 
TLE1, and BCL9. Furthermore, we observed that TNF, LTB, 
ITGB2, and CD2 interact with each other and are associated 
with the immune response, whereas TLE1 and BCL9 interact 
with each other and are associated with gene expression, thus 
indicating that HIV infection might affect the methylation pat-
tern of immune response-related genes and transcription fac-
tors. Interestingly, no interaction has been reported between 
HIV and TRIM69, which is involved in induction of apoptosis 
and, in this study, was hypomethylated in EC, thus suggesting 
that its expression might be associated with control of HIV in 
the absence of cART.
Overall, these data suggest that HIV infection modifies 
levels of cellular host genome methylation and that meth-
ylation levels might be associated with progression of HIV 
infection.
The T-Cell Receptor Signaling Pathway Is Enriched in Differentially 
Methylated CpG Sites in Viremic Individuals
To determine the cellular pathways associated with statistically 
significant differences in methylation at CpG sites located in a 
promotor region and with a fold-change >5%, we performed a 
KEGG pathway enrichment analysis using the previously listed 
genes related to these CpG sites. We observed 58 differentially 
enriched cellular pathways (Supplementary Table 7), from 
which 5 were enriched in the comparisons of viremic versus 
cART-suppressed, versus EC individuals, and versus HIVneg; 
the “T-cell receptor signaling pathway” was the most signifi-
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Greater Promoter TNF Methylation as a Counteraction of TNF 
Overexpression in Viremic Individuals
To characterize the effect of HIV viremia on methylation, 
mRNA expression, and plasma levels of TNF, we quantified the 
plasma level of TNF in the discovery cohort, and the methyl-
ation, mRNA expression, and plasma levels of TNF in longi-
tudinal samples (before and after initiation of cART) from 5 
independent individuals with HIV. We observed greater plasma 
levels of TNF in viremic individuals than in cART-suppressed, 
EC, and HIV-negative individuals, as well as in EC versus 
HIVneg (Figure 3A). These data suggest that hypermethylation 
of TNF promoter might be a homeostatic mechanism for nor-
malization of TNF production and therefore immune activa-
tion due to HIV infection. In the validation cohort, we did 
not observe significant changes in specific DNA methylation 
































Figure 1. Genome-wide methylation levels by CpG site. (A) HIV-negative (HIVneg) vs viremic, (B) viremic vs cART, (C) viremic vs EC, and (D) HIVneg vs EC. From inside to 
outside: (i) heatmap of CpGs with significant adjusted P-value and differential methylation over 5%, following the order of the group comparison (no significant differences 
in methylation of CpG sites were detected in HIVneg vs EC, D); (ii) Manhattan plot of –log10(P-value) for CpG sites with P-value thresholds at 10
−5 and 10−7; and (iii) chromo-
somes. CpG sites for which differences in methylation were statistically significant are shown in blue (hypomethylated) and red (hypermethylated). The density of CpG sites 
per chromosome is color-coded. Abbreviations: cART, combination antiretroviral therapy; CpG, cytosine-guanine; EC, elite controllers; HIV, human immunodeficiency virus; 
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Figure 2. Analysis pipeline overview, methylation level of genes of interest, and interaction between genes of interest and HIV. A, Schematic representation of the bi-
oinformatics analysis pipeline overview, (B) the methylation level of the differentially methylated genes of interest, and (C) the interaction between the genes of interest 
(using STRING) and HIV (based on previous bibliography). The methylation level is shown in blue (hypomethylated) and red (hypermethylated). Abbreviations: cART, combined 
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longitudinal samples pre- and post-viral suppression by cART 
(Figure 3B, C). However, we observed a decrease in the plasma 
level of TNF after initiation of cART (Figure 3D). These results 
corroborate that initiation of cART, which suppresses HIV vi-
remia, helps to decrease plasma TNF levels [14] and therefore 
can partially contribute to the reduction of global immune ac-
tivation under suppressive cART.
DISCUSSION
The present study is the first to our knowledge to evaluate 
the genome-wide DNA methylation profile in vivo in periph-
eral CD4+ T cells from HIV-negative individuals and indi-
viduals with HIV with different phenotypes of viral control 
(EC) and degrees of disease progression (viremic and paired 
cART-suppressed and EC individuals). We observed differen-
tial genome-wide patterns depending on spontaneous ability 
to control HIV replication and on whether or not suppressive 
cART had been initiated.
Several studies performed in vitro and in vivo have analyzed 
how HIV affects host epigenetic mechanisms [11, 13, 15, 16]. 
On the one hand, viral infection alters the expression of cellular 
genes that modify chromatin structure. On the other hand, the 
viral genome itself is modified by some of these mechanisms to 
regulate its level of transcription [5]. Moreover, lifestyle (eg, nu-
trition, physical activity, working habits, smoking, and alcohol 
consumption) and the administration of drugs, such as cART, 
may influence epigenetic mechanisms [17].
In our study, we observed 129 differentially methylated CpG 
sites in viremic versus HIVneg individuals, 162 sites in viremic 
versus cART individuals, and 441 sites in viremic versus EC 
individuals. These results confirm not only that HIV infection 
modifies the DNA methylation profile of the target cells in vivo 
[11–13] but also that these epigenetic modifications differ ac-
cording to HIV disease progression status and control of infec-
tion [9].
Regarding specific genes, we found that hypermethylation 







































































































Figure 3. Association between HIV infection, cART, and disease progression on TNF production. A, Plasma TNF level in HIV-negative, viremic, cART, and EC individuals 
from the discovery cohort (n = 12 HIVneg, n = 20 viremic, n = 21 cART, and n = 19 EC). B, Levels of TNF-specific methylation, (C) mRNA, and (D) plasma in the validation co-
hort (n = 5, samples before [BL, baseline], and 1 and 2 years after initiation of cART [ART1 and ART2]). Solid symbols represent undetectable values. The statistical analysis 
was performed using the Wilcoxon signed rank test (paired comparisons: viremic vs cART) or Mann-Whitney test (nonpaired comparisons: viremic vs EC and HIVneg, and EC 
vs HIVneg) [GraphPad Prism (v5.0)]. Abbreviations: cART, combined antiretroviral therapy; EC, elite controllers; HIV, human immunodeficiency virus; mRNA, messenger RNA; 
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individuals. Several studies have shown that TNF and TNF re-
ceptor superfamily members have a role in the pathogenesis of 
HIV, affecting different stages of the HIV replication cycle and 
being able to increase HIV transcription through activation 
of the NF-κB signaling pathway [18]. Moreover, it has been 
shown that expression of TNF is regulated by DNA methyla-
tion and other mechanisms [19], and that TNF acts as a link 
between T-cell dysfunction and chronic inflammation during 
chronic viral infection [20]. The hypermethylation of the TNF 
promoter region and greater plasma levels in viremic individ-
uals we observed might constitute a homeostatic mechanism 
for downregulation of TNF expression and plasma levels in 
order to decrease immune activation and HIV expression. 
On the other hand, TNF produced by other cell types, such 
as CD8+ T cells, monocytes, and dendritic cells, which we did 
not include in this study, should be further characterized in 
future studies.
With respect to differences in methylation between viremic 
and EC individuals, we observed that the genes TRIM69, 
and ITGB2, were hypomethylated in EC. These results sug-
gest that the expression of these genes might be upregulated 
and therefore play a role in the control of HIV replication in 
the absence of cART. To our knowledge, TRIM69, which en-
codes a member of the RING-B-box-coiled-coil family and 
which, when overexpressed, induces apoptosis, and although 
its DNA methylation has been associated with HIV frailty 
[21], it has never been related to HIV replication or pathogen-
esis. Its hypomethylation in EC may increase its expression in 
CD4+ T cells and therefore in HIV-infected cells, causing spe-
cific apoptosis of these cells and potentially leading to better 
control of HIV infection. Interactions between the HIV repli-
cation cycle and the LTB, ITGB2, CD2, and TLE1 genes have 
already been described [22–35]. ITGB2 encodes an integrin 
beta chain, which plays an important role in the immune re-
sponse by helping leukocytes gather at sites of infection or 
injury, where they are needed to contribute to the immune re-
sponse. Hypomethylation of ITGB2 in EC may upregulate their 
expression, thus enhancing the immune response against HIV 
and potentially helping to control HIV infection in the absence 
of cART.
The methylation pattern found when we compared viremic 
versus HIVneg and EC, and consisting of LTB hypermethylation 
and TLE1 hypomethylation, defines a hallmark of pathogenic 
HIV infection not reverted by cART. LTB is a type II mem-
brane protein of the TNF family and an inducer of the inflam-
matory response system and is involved in the development 
of lymphoid tissue. TLE1 is a transcription factor that inhibits 
NF-κB and Wnt signaling pathways, which are involved in 
activation of HIV transcription [36]. Conversely, the lack of 
hypomethylation of TLE1 in EC may prevent increased ex-
pression, thus decreasing its impact on the NF-κB and Wnt 
signaling pathways, enhancing HIV antigen expression, and 
therefore helping to detect and eliminate HIV-infected cells, 
which could contribute to the lower reservoir levels described 
in EC. Interestingly, none of the abovementioned genes has ever 
been related to control of HIV infection or disease progression. 
Therefore, further investigation of these genes and their role in 
HIV infection could prove helpful for deciphering the mech-
anisms that may regulate HIV control in EC, controllers, and 
long-term nonprogressors.
BCL9, which is involved in WNT pathway and required for 
HIV transcription [37], was hypermethylated in the viremic 
samples compared with cART-suppressed samples, whereas its 
methylation pattern in viremic individuals was similar to that of 
HIVneg donors, suggesting that its expression might be lower in 
viremic individuals as a mechanism for reducing replication of 
HIV or as a direct effect of cART. CD2 is a surface antigen that 
interacts with LFA3 (CD58) on antigen-presenting cells to opti-
mize immune recognition, and its expression in resting memory 
CD4+ T cells has been related to latently HIV-infected cells [34]. 
In contrast, CD2 has been positively associated with the expres-
sion of restriction factors [32], and its hypermethylation in vi-
remic individuals was downregulated by cART, suggesting that 
its increased expression might favor HIV replication.
The limitations of the study should be acknowledged. First, a 
low number of individuals was analyzed in both the discovery 
and the validation cohorts. This may explain why we did not 
observe statistically significant differences in the methylation of 
CpG sites when comparing EC with HIVneg. Second, although 
cART may have an impact on epigenetics, the low number of 
individuals and the different cART regimens they were taking 
prevented us from determining changes in DNA methylation 
related to the specific antiretroviral drugs used. Third, although 
age and sex bias are undesirable, there is no evidence of a strong 
influence of either variable on the methylation level of our can-
didate genes. Moreover, most aging-related studies focus on 
epigenetic reprogramming during early development [38] or 
on cohorts with considerable variation in age that exceed the 
10 years found among some of our study groups. As for the sex 
composition of our cohorts, we excluded all CpG located in the 
X chromosome and in imprinted genes [39]. In this sense, little 
is known about sex-specific variations in methylation patterns 
for sequences of coding genes in autosomal chromosomes. 
Finally, as latently infected cells cannot be differentiated from 
uninfected cells and represent 1 in 1000 total CD4 T cells [40], 
we were not able to specifically analyze the infected peripheral 
CD4+ T-cell subset. Thus, noninfected cells might dilute the 
changes in host DNA methylation. However, by analyzing total 
CD4+ T cells, we can assume that the changes observed in the 
DNA methylation patterns may be due to HIV infection itself 
and to bystander effects in noninfected cells.
Data on changes in host genes after in vivo infection are lim-
ited, thus highlighting the need for more comprehensive global 
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help to isolate the several types of cells representing the im-
mune system and interacting with the virus and to compare 
changes in gene and protein expression, as well as epigenetic 
modifications.
Our findings confirm that HIV infection modifies host ge-
nome methylation patterns in vivo and that these patterns differ 
and may play a role in progression of HIV infection.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
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